- The Phase 1 Study will Evaluate Eflornithine in Combination with Temozolomide - PALO ALTO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage...
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine
PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete. The STELLAR study completed full enrollment with a total of 343 patients.
PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 3432872 entitled “Compositions and Methods for Use of Eflornithine and Derivatives and Analogs thereof to Treat Cancers, Including Gliomas,” by the European Patent Office (EPO).
PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced a positive outcome of the pre-planned interim analysis for futility in its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma.
PALO ALTO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 10,786,470 entitled “Formulations for Administration of Eflornithine,” by the United States Patent and Trademark Office (USPTO).
PALO ALTO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 10,786,470 entitled “Formulations for Administration of Eflornithine,” by the United States Patent and Trademark Office (USPTO).